MIRACLE / MIRACLE ICD (Multicenter InSync / ICD Randomized Clinical Evaluation) studies: initiated in 1998 and 1999, respectively, evaluated NYHA Class III, IV patients for six months and demonstrated significant improvements in quality of life and cardiac function.
The results reinforce evidence from earlier Medtronic-supported trials, such as MUSTIC, MIRACLE and MIRACLE ICD, that have shown dramatic benefits of CRT for many heart failure patients, including improved exercise capacity, quality of life and clinical symptoms.
Physicians will evaluate the performance of the Medtronic Attain SD cardiac vein lead model 4189, as part of the ongoing MIRACLE ICD trial (Multicenter InSync Randomized Clinical Evaluation in ICD patients).
Other major clinical trials supported by Medtronic such as MUSTIC, MIRACLE and MIRACLE ICD have shown dramatic benefits of CRT for many heart failure patients, including improved exercise capacity, quality of life and clinical symptoms.
The study, called MIRACLE ICD II, evaluated the use of cardiac resynchronization therapy defibrillators in patients with mild symptoms, and showed that these patients demonstrated significant improvement in both cardiac structure and function, as well as improvements in their overall clinical response.
Evidence supporting the benefits of cardiac resynchronization therapy (CRT) for heart failure patients continues to mount, with results of the MIRACLE ICD clinical study published in the May 28 issue of the Journal of the American Medical Association (JAMA).